{"disease":{"id":"nsclc-stage-iiib","name":"nsclc stage iiib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03509779","title":"Pronostic and Predictive Value of EMT in Localized Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"European Georges Pompidou Hospital","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT06829641","title":"Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05132218","title":"Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04042558","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT06374160","title":"Exercise in Patients With Advanced Non-small Cell Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04768491","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT06780839","title":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05816499","title":"Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03620669","title":"1st Line Durvalumab in PS 2 NSCLC Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT03805841","title":"Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Rain Oncology Inc","has_results":true},{"nct_id":"NCT03647956","title":"Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05988697","title":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04223596","title":"Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT04147351","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03515252","title":"Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Ivy Life Sciences, Co., Ltd","has_results":false},{"nct_id":"NCT04865250","title":"Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT04932343","title":"Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04909034","title":"A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Microbio Co Ltd","has_results":false},{"nct_id":"NCT03231475","title":"Phase I Study of SPH1188-11 in NSCLC","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shanghai Pharmaceuticals Holding Co., Ltd","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}